The "KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The global market for KRAS inhibitors has seen ...

4 月 1 日，CDE 官网显示，海博为药业申报的 1 类新药 HBW-012336胶囊获批临床，用于携带 KRAS G12D 突变的局部晚期或转移性实体瘤。这也是该药在国内首次获批IND。 截图来源：CDE 官网 HBW-012336 是一款口服 KRAS G12D 抑制剂，该药不仅解决了 G12D 抑制剂口服生物利用度低的国际性难题，还具有高活性、高选择性、高组织靶向性及强效抗肿瘤活性等突出优 ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

QTX3544 is an oral, G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor currently being evaluated in a Phase 1 clinical trial in patients with KRASG12V mutations. The mitogen-activated ...

In 2021, the first KRAS inhibitor was approved to treat non-small cell lung cancer with KRAS G12C mutations, but with longer ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

ALTA3263 is an oral KRAS-selective inhibitor specifically designed to potently inhibit the KRAS “ON” (active) state of greater than 90% of all KRAS mutations and to provide complete target ...

When one of the proteins in the pathway is mutationally activated, it can drive tumor development and growth. RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in ...

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...

QTX3034 is an allosteric multi-KRAS inhibitor with G12D-preferring activity. QTX3046 is an allosteric KRAS G12D-selective, dual ON/OFF state inhibitor. Both QTX3034 and QTX3046 Phase 1 clinical ...